69 related articles for article (PubMed ID: 38604813)
21. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
22. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hogg D; Hill A; Márquez-Rodas I; Haanen J; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bastholt L; Rizzo JI; Balogh A; Moshyk A; Hodi FS; Wolchok JD
N Engl J Med; 2019 Oct; 381(16):1535-1546. PubMed ID: 31562797
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of Melanoma: Facts and Hopes.
Weiss SA; Wolchok JD; Sznol M
Clin Cancer Res; 2019 Sep; 25(17):5191-5201. PubMed ID: 30923036
[TBL] [Abstract][Full Text] [Related]
24. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
[TBL] [Abstract][Full Text] [Related]
25. Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.
Künkele A; Brown C; Beebe A; Mgebroff S; Johnson AJ; Taraseviciute A; Rolczynski LS; Chang CA; Finney OC; Park JR; Jensen MC
Biol Blood Marrow Transplant; 2019 Feb; 25(2):223-232. PubMed ID: 30315942
[TBL] [Abstract][Full Text] [Related]
26. Mouse Models for Cancer Immunotherapy Research.
Olson B; Li Y; Lin Y; Liu ET; Patnaik A
Cancer Discov; 2018 Nov; 8(11):1358-1365. PubMed ID: 30309862
[TBL] [Abstract][Full Text] [Related]
27. IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells.
Ward NC; Yu A; Moro A; Ban Y; Chen X; Hsiung S; Keegan J; Arbanas JM; Loubeau M; Thankappan A; Yamniuk AP; Davis JH; Struthers M; Malek TR
J Immunol; 2018 Nov; 201(9):2579-2592. PubMed ID: 30282751
[TBL] [Abstract][Full Text] [Related]
28. Immune system augmentation via humanization using stem/progenitor cells and bioengineering in a breast cancer model study.
Shafiee A; McGovern JA; Lahr CA; Meinert C; Moi D; Wagner F; Landgraf M; De-Juan-Pardo E; Mazzieri R; Hutmacher DW
Int J Cancer; 2018 Sep; 143(6):1470-1482. PubMed ID: 29659011
[TBL] [Abstract][Full Text] [Related]
29. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
[TBL] [Abstract][Full Text] [Related]
30. Regulatory T cells control toxicity in a humanized model of IL-2 therapy.
Li Y; Strick-Marchand H; Lim AI; Ren J; Masse-Ranson G; Dan Li ; Jouvion G; Rogge L; Lucas S; Bin Li ; Di Santo JP
Nat Commun; 2017 Nov; 8(1):1762. PubMed ID: 29176694
[TBL] [Abstract][Full Text] [Related]
31. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
[TBL] [Abstract][Full Text] [Related]
32. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao CD; Wagstaff J; Schadendorf D; Ferrucci PF; Smylie M; Dummer R; Hill A; Hogg D; Haanen J; Carlino MS; Bechter O; Maio M; Marquez-Rodas I; Guidoboni M; McArthur G; Lebbé C; Ascierto PA; Long GV; Cebon J; Sosman J; Postow MA; Callahan MK; Walker D; Rollin L; Bhore R; Hodi FS; Larkin J
N Engl J Med; 2017 Oct; 377(14):1345-1356. PubMed ID: 28889792
[TBL] [Abstract][Full Text] [Related]
33. T memory stem cells in health and disease.
Gattinoni L; Speiser DE; Lichterfeld M; Bonini C
Nat Med; 2017 Jan; 23(1):18-27. PubMed ID: 28060797
[TBL] [Abstract][Full Text] [Related]
34. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Alva A; Daniels GA; Wong MK; Kaufman HL; Morse MA; McDermott DF; Clark JI; Agarwala SS; Miletello G; Logan TF; Hauke RJ; Curti B; Kirkwood JM; Gonzalez R; Amin A; Fishman M; Agarwal N; Lowder JN; Hua H; Aung S; Dutcher JP
Cancer Immunol Immunother; 2016 Dec; 65(12):1533-1544. PubMed ID: 27714434
[TBL] [Abstract][Full Text] [Related]
35. Mouse models in oncoimmunology.
Zitvogel L; Pitt JM; Daillère R; Smyth MJ; Kroemer G
Nat Rev Cancer; 2016 Dec; 16(12):759-773. PubMed ID: 27687979
[TBL] [Abstract][Full Text] [Related]
36. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.
Sanmamed MF; Chester C; Melero I; Kohrt H
Ann Oncol; 2016 Jul; 27(7):1190-8. PubMed ID: 26912558
[TBL] [Abstract][Full Text] [Related]
37. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Charych DH; Hoch U; Langowski JL; Lee SR; Addepalli MK; Kirk PB; Sheng D; Liu X; Sims PW; VanderVeen LA; Ali CF; Chang TK; Konakova M; Pena RL; Kanhere RS; Kirksey YM; Ji C; Wang Y; Huang J; Sweeney TD; Kantak SS; Doberstein SK
Clin Cancer Res; 2016 Feb; 22(3):680-90. PubMed ID: 26832745
[TBL] [Abstract][Full Text] [Related]
38. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
39. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
[TBL] [Abstract][Full Text] [Related]
40. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Buchbinder EI; Desai A
Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]